{"schema_version":"secwatch.filing_event.v1","accession":"0001638833-24-000006","form_type":"8-K","ticker":"SGRY","cik":"0001638833","company_name":"Surgery Partners, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.939298+00:00","generated_at":"2026-06-07T02:21:02.517650+00:00","sec_items":["2.02"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Surgery Partners reaffirms 2023 guidance, projects 2024 Adj. EBITDA >$495M","bullets":["Reaffirmed 2023 Adjusted EBITDA guidance of $436M-$440M; revenue ~$2.75B.","Projected 2024 Adjusted EBITDA greater than $495 million, implying ~13% YoY growth.","Guidance based on results through November 2023, subject to year-end adjustments.","Company updated investors at J.P. Morgan Healthcare Conference on January 8, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001638833-24-000006","json":"https://secwatch.observer/filing/0001638833-24-000006.json","markdown":"https://secwatch.observer/filing/0001638833-24-000006.md","text":"https://secwatch.observer/filing/0001638833-24-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638833/000163883324000006/0001638833-24-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638833/000163883324000006/sgry-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:21:02.517650+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"299b17ad8f64d1e6a71413a9ff4cc4d3e8c6f568","claim":"Surgery Partners, Inc. reported 2023 results: revenue approximately $2.75 billion. Guidance reaffirmed.","evidence_excerpt":"Based on results through November 2023, the Company is re-affirming its 2023 Adjusted EBITDA guidance of $436 million to $440 million and its 2023 Revenue guidance of approximately $2.75 billion.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638833/000163883324000006/0001638833-24-000006-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2023"},{"label":"Revenue","value":"approximately $2.75 billion"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"ef64e99b904791dae3df2e775150e28a99d604a1","claim":"Surgery Partners, Inc. updated its 2024 guidance (initiated).","evidence_excerpt":"In addition, the Company projects 2024 Adjusted EBITDA to be greater than $495 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638833/000163883324000006/0001638833-24-000006-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2024"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}